Trial Profile
A Phase 2a, Double Blind, Placebo Controlled, Multicenter, Dose Escalation Study to Evaluate the Safety and Efficacy of BIO 11006 Inhalation Solution in Subjects With COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2011
Price :
$35
*
At a glance
- Drugs BIO-11006 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms BREATH-1
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
- 09 Feb 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 09 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.